Skip to Main Content

Author Details

Bernard Zinman
Mount Sinai Hospital, University of Toronto
1966
651
112
PMIDPaper TitleJournal TitlePublished Year
37758044Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.Am Heart J2024
36657983Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes.Diabetes Care2023
37852075Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk.J Diabetes Complications2023
37612415Deteriorating beta cell function is the dominant determinant of progression from normal glucose tolerance to prediabetes/diabetes in young women following pregnancy.Diabetologia2023
37500612Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes.Nat Commun2023
37384110Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.Am J Prev Cardiol2023
37449424Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials.Stroke2023
37311602Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.BMJ Open Diabetes Res Care2023
37380623Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function.Diabetes Obes Metab2023
36889425Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.Am J Kidney Dis2023
36548707Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448.Diabetes Care2023
36746160Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.Lancet Diabetes Endocrinol2023
36602334Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy.Diabetes Care2023
36894921The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.Cardiovasc Diabetol2023
34532950The ongoing evolution of basal insulin therapy over 100â¿¿years and its promise for the future.Diabetes Obes Metab2022
35671033Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?Diabetes Care2022
35394821Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.Circulation2022
35972222Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial.Diabetes Care2022
36244997The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.Nat Commun2022
35929472Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.J Am Heart Assoc2022
36321737Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes.Diabetes Care2022
35290464Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?J Clin Endocrinol Metab2022
35015817Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.Diabetes Care2022
35314257Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.Diabetes Res Clin Pract2022
35007329Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.Diabetes Care2022
34903039Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.Circulation2022
35172198The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.Diabetes Metab2022
35259243Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life.Diabetes Care2022
35229024Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.Alzheimers Dement (N Y)2022
35166009Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.Diabetes Obes Metab2022
34558768Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial.Diabetes Obes Metab2022
33181154Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.Kidney Int2021
33769679The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.Diabetes Obes Metab2021
33826916Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials.Cell Metab2021
33492422The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement.Diabetologia2021
33619120Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.Clin J Am Soc Nephrol2021
33564423Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.Clin Kidney J2021
33754809Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.J Am Heart Assoc2021
33559704Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.Diabetologia2021
33502090Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.Diabetes Obes Metab2021
35005582Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.EClinicalMedicine2021
34463409Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.Diabetes Obes Metab2021
34746711Subtypes of gestational diabetes and future risk of pre-diabetes or diabetes.EClinicalMedicine2021
34476096Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial.Clin Kidney J2021
34132492Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.ESC Heart Fail2021
34325887Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.JACC Heart Fail2021
33956387Short-term intensive insulin as induction and maintenance therapy for the preservation of beta-cell function in early type 2 diabetes (RESET-IT Main): A 2-year randomized controlled trial.Diabetes Obes Metab2021
34031968Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.Eur J Heart Fail2021
33950573Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.Diabetes Obes Metab2021
34001534Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort.Diabetes Care2021
  • 1 - 50 of 651

Recommended Authors

Adam Buckley
Imperial College London Diabetes Centre
Career Start Year 2015
Number of shared co-authors 0
Lisa R Staimez
Rollins School of Public Health, Emory University
Career Start Year 2012
Number of shared co-authors 0
Pavithra Vijayakumar
Yale School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Anna R Kahkoska
University of North Carolina at Chapel Hill
Career Start Year 2011
Number of shared co-authors 3
Klara R Klein
University of North Carolina School of Medicine
Career Start Year 2010
Number of shared co-authors 2
Matthew Freeby
David Geffen School of Medicine university of california los angeles.
Career Start Year 2006
Number of shared co-authors 0
Anders Gummesson
Sahlgrenska University Hospital
Career Start Year 2005
Number of shared co-authors 0
Nicole Ehrhardt
University of Washington
Career Start Year 2005
Number of shared co-authors 0
Nestoras Mathioudakis
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 2
Masahide Hamaguchi
Kyoto Prefectural University of Medicine
Career Start Year 2004
Number of shared co-authors 0
James R Bain
Duke University Medical Center
Career Start Year 2002
Number of shared co-authors 1
Amit R Majithia
University of California
Career Start Year 1999
Number of shared co-authors 0
Michael R Rickels
Hospital of the University of Pennsylvania
Career Start Year 1995
Number of shared co-authors 3
Carol Forsblom
Folkhalsan Institute of Genetics, Folkhalsan Research Center
Career Start Year 1992
Number of shared co-authors 7
Naoki Sakane
Clinical Research Institute, National Hospital Organization Kyoto Medical Center
Career Start Year 1992
Number of shared co-authors 0
Andrew D Morris
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 7
Steven M Willi
Children's Hospital of Philadelphia
Career Start Year 1991
Number of shared co-authors 2
Robert M Cohen
University of Cincinnati and Cincinnati VA Medical Center
Career Start Year 1987
Number of shared co-authors 2
Michael J Muehlbauer
Duke University School of Medicine
Career Start Year 1987
Number of shared co-authors 1
Steven A Smith
Mayo Clinic
Career Start Year 1987
Number of shared co-authors 0
G??rard Waeber
Centre hospitalier universitaire vaudois
Career Start Year 1986
Number of shared co-authors 5
Wolfgang Rathmann
German Center for Diabetes Research
Career Start Year 1984
Number of shared co-authors 5
Irene M Stratton
Gloucestershire Hospitals NHS Foundation Trust
Career Start Year 1983
Number of shared co-authors 1
Diana Barb
University of Florida
Career Start Year 1982
Number of shared co-authors 0
Merri L Pendergrass
Banner-University Medicine Endocrinology and Diabetes Clinic
Career Start Year 1981
Number of shared co-authors 0
Fernando Ovalle
Comprehensive Diabetes Center, University of Alabama at Birmingham
Career Start Year 1981
Number of shared co-authors 0
Roberto Vettor
University Hospital of Padova
Career Start Year 1979
Number of shared co-authors 0
Km Venkat Narayan
Rollins School of Public Health, Emory University
Career Start Year 1979
Number of shared co-authors 3
Carla J Greenbaum
Center for Interventional Immunology, Benaroya Research Institute at Virginia Mason
Career Start Year 1977
Number of shared co-authors 2
Richard David Leslie
Blizard Institute, Barts and Royal London Medical School
Career Start Year 1977
Number of shared co-authors 0

Collaborators

Robert A Hegele
Co-authored papers 67
John B Buse
University of North Carolina
Co-authored papers 43
David M Nathan
Co-authored papers 24
Kenneth W Mahaffey
Stanford University Medical School
Co-authored papers 16
Ian H de Boer
and the Kidney Research Institute, University of Washington
Co-authored papers 15
Christopher P Cannon
Brigham and Women's Hospital
Co-authored papers 14
David Z I Cherney
University Health Network, University of Toronto
Co-authored papers 14
Salim Yusuf
Co-authored papers 11
Michael W Steffes
Co-authored papers 11
Deepak L Bhatt
Icahn School of Medicine at Mount Sinai Health System
Co-authored papers 11
Carol M Anderson
University of California san francisco
Co-authored papers 8
Ronald Klein
University of Wisconsin School of Medicine and Public Health
Co-authored papers 8
Naveed Sattar
Co-authored papers 7
Judith A Miller
University of Toronto
Co-authored papers 7
Andrew A House
The Lilibeth Caberto Kidney Clinical Research Unit, Western University
Co-authored papers 6
Vesta Lai
Toronto General Hospital (Y.L.
Co-authored papers 5
James W Scholey
University Health Network, University of Toronto
Co-authored papers 5
Andrew D Paterson
The Hospital for Sick Children
Co-authored papers 5
Stephen W Scherer
The Hospital for Sick Children
Co-authored papers 5
John H Alexander
Duke University Medical Center
Co-authored papers 5
Heather N Reich
University Health Network and University of Toronto
Co-authored papers 5
Athena Philis-Tsimikas
Scripps Whittier Diabetes Institute
Co-authored papers 5
Juliana C N Chan
Co-authored papers 4
John R McLaughlin
University of Toronto Dalla Lana School of Public Health
Co-authored papers 4
Lap-Chee Tsui
The University of Hong Kong
Co-authored papers 4
Julia A Knight
Co-authored papers 4
Nayyar Iqbal
Pondicherry Institute of Medical Sciences
Co-authored papers 4
Adrian F Hernandez
Duke University Medical Center
Co-authored papers 4
George Tomlinson
University Health Network
Co-authored papers 4
Rose A Gubitosi-Klug
Co-authored papers 4
Release 1.2